HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.

Abstract
Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF.7, BQ.1.1, and XBB against neutralizing antibodies from vaccination, hybrid immunity, and breakthrough infections 4-6 months after vaccination and infection. We show that a two-dose CoronaVac or a third-dose ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after vaccination. Hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections induce long-term persistence of the antibody response, and over 70% of sera neutralize BA.1, BA.2, BA.4/BA.5, and BF.7. However, BQ.1.1 and XBB, followed by BA.2.75, are more resistant to neutralization, with neutralizing titer reductions of ∼9- to 41-fold, ∼16- to 63-fold, and ∼4- to 25-fold, respectively. These data highlight additional vaccination in CoronaVac- or ZF2001-vaccinated individuals and provide insight into the durability of neutralization against Omicron subvariants.
AuthorsKa-Li Zhu, Xiao-Lin Jiang, Bing-Dong Zhan, Xue-Jun Wang, Xian Xia, Guo-Ping Cao, Wen-Kui Sun, Peng-Xiang Huang, Jin-Zhong Zhang, Yu-Ling Gao, Er-Hei Dai, Hui-Xia Gao, Mai-Juan Ma
JournalCell reports (Cell Rep) Vol. 42 Issue 2 Pg. 112075 (02 28 2023) ISSN: 2211-1247 [Electronic] United States
PMID36774551 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Chemical References
  • ZF2001 COVID-19 vaccine
  • sinovac COVID-19 vaccine
  • Antibodies, Neutralizing
  • Antibodies, Viral
Topics
  • Humans
  • Breakthrough Infections
  • COVID-19 (prevention & control)
  • SARS-CoV-2
  • Antibodies, Neutralizing
  • Antibodies, Viral

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: